PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant
progress in the development of its lead therapeutic candidate
KSI-301. The R&D event, including a live video stream, will be
held on Monday, October 14 from 8:00
– 10:30a.m. Pacific Time in
San Francisco, CA.
At the R&D Day, Kodiak senior management, leading retina
specialists, and market analysts will provide an in-depth look at
Kodiak's Antibody Biopolymer Conjugate platform for high-prevalence
retinal diseases, the market opportunity including the evolving
commercial landscape, the latest KSI-301 clinical data, and the
company's clinical development and filing strategy.
"In addition to sharing the most recent KSI-301 clinical data in
patients with retinal vascular diseases at the AAO Retina
Subspecialty Day, we are excited to be bringing together a group of
experts to offer their individual and shared perspectives on the
unmet needs for patients, the potential benefits of a medicine like
KSI-301 offering long-interval dosing, and a view into the
commercial opportunities," said Victor
Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
"We also look forward to sharing more about Kodiak's development
plans and path to potential licensure for KSI-301."
The R&D Day will be hosted by members of the Kodiak senior
management team:
- Victor Perlroth, M.D., Chairman
and Chief Executive Officer
- Jason Ehrlich, M.D., Ph.D.,
Chief Medical Officer and Chief Development Officer
- John Borgeson, Chief Financial
Officer
The event will include presentations and discussions with the
following guest speakers:
- Carl Regillo, M.D., FACS – Wills
Eye Hospital and Mid Atlantic Retina, Philadelphia, PA. Dr. Regillo will focus on
KSI-301 in wet AMD.
- Charles Wykoff, M.D., Ph.D. –
Retina Consultants of Houston,
Houston, TX. Dr. Wykoff will focus
on KSI-301 in diabetic eye diseases with emphasis on diabetic
macular edema and non-proliferative diabetic retinopathy.
- Arshad Khanani, M.D., M.A. –
Sierra Eye Associates, Reno, NV.
Dr. Khanani will focus on KSI-301 in retinal vein occlusion
(RVO).
- Max Cambras – L.E.K. Consulting,
Life Sciences & Pharma, Los Angeles,
CA. Mr. Cambras will focus on the market opportunity for an
anti-VEGF agent with extended durability.
- Nancy Holekamp, M.D. – Pepose
Vision Institute, St. Louis, MO.
Dr Holekamp will provide a synthesis of the discussion and view
into KSI-301's potential clinical impact.
The event will conclude with a panel discussion involving the
guest speakers together with Kodiak senior management and will
provide an opportunity for Q&A.
A live webcast of the R&D Day will be available on the
"Investors & Media" section of Kodiak's website at
http://ir.kodiak.com/. Replays will be available on the Kodiak
website for 90 days following the event.
Investors, equity research analysts and others interested in
attending the event in person may contact ir@kodiak.com.
About KSI-301
KSI-301 is an investigational therapy built on the Company's
proprietary ABC Platform and is designed to maintain potent and
effective drug levels in ocular tissues for longer than existing
agents. Kodiak's objective with KSI-301 is to develop a new
first-line agent to improve outcomes for patients with retinal
vascular diseases and to enable earlier treatment and prevention of
vision loss for patients with diabetic eye disease. KSI-301 is
being developed and is fully owned globally by Kodiak Sciences
Inc.
About Kodiak Sciences Inc.
Kodiak™ is a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component. Kodiak
is based in Palo Alto, CA. For
more information, visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies, future development
plans, clinical and regulatory objectives and the timing thereof,
anticipated design of planned clinical trials, expectations
regarding the potential efficacy and commercial potential of our
product candidates, including KSI-301, the anticipated presentation
of data, the results of our research and development efforts and
our ability to advance our product candidates into later stages of
development. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as "may,"
"will," "should," "would," "expect," "plan," "believe," "intend,"
"pursue," and other similar expressions among others. Any
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the preliminary safety, efficacy and
durability data for our KSI-301 product candidate from the Phase 1
study will not continue or persist; cessation or delay of any of
the ongoing clinical studies and/or our development of KSI-301 may
occur; future potential regulatory milestones of KSI-301, including
those related to current and planned clinical studies may be
insufficient to support regulatory submissions or approval;
anticipated presentation of data at upcoming conferences may not
occur; our research and development efforts and our ability to
advance our product candidates into later stages of development may
fail; any one or more of our product candidates may not be
successfully developed, approved or commercialized; adverse
conditions in the general domestic and global economic markets; as
well as the other risks identified in our filings with the
Securities and Exchange Commission. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors"
in our most recent Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and
Kodiak undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance
on such forward-looking statements.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-host-rd-day-on-october-14-in-san-francisco-to-highlight-recent-clinical-progress-and-development-planning-for-ksi-301-300937044.html
SOURCE Kodiak Sciences Inc.